**Conflict of Interest**

All authors declare that they have no conflicts of interest for this publication.

General conflicts of interest of the authors:

1.Speaker and medical advisor for Takeda; speaker for CSL Behring, Pint Pharma. 2.Speaker, medical advisor and training scholarships for Takeda. Training scholarship for CSL Behring. 4. Speaker for Takeda and CSL Behring. 5.Speaker for: Shire/Takeda, CSL Behring, Novartis and Sanofi. Financial support for advisory board/expert meetings: Shire/Takeda, CSL Behring. 6. Speaker for Takeda, Pint Pharma 7. Speaker for: Takeda, CSL Behring. 8. Speaker for CSL Behring, Medical Advisor for Takeda. 9. Speaker and medical advisory for Takeda and Novartis. 10. Fees for presentations, educational and research support from Sanofi, Eurofarma, Novartis,GSK, Phoenix, Stallergenes, and Takeda. Member of the Advisory Board of Takeda. 11. Speaker for Pint Pharma. 12. Speaker for: Takeda. 14. Speaker for Takeda. 15. Speaker for Takeda, Pharming, Biocryst, CSL Behring. Medical Advisor: Pharming and Takeda.16. Speaker for Takeda. 17. Speaker for Takeda. 21. Speaker for Takeda. 22. Speaker for Takeda. 24. Speaker, medical advisor and training scholarships for Takeda. 25. Speaker for Takeda, Bagó, Elea/Phoenix, Glaxo, Roemmer. 26. Speaker for Takeda and Novartis. 28. Speaker and medical advisory for Takeda. 29. Speaker and consultant for Takeda. 31. Speaker and consultant for Shire/Takeda and CSL Behring. Grant of researcher initiative from Shire/Takeda (IST-BRA-00078)